Back to search results

Spinal Cord Stimulation for ARDS Patients on Ventilators

This study is looking at a new way to help patients with Respiratory Distress Syndrome (ARDS) who are on a ventilator. It uses a device called the Transcutaneous Biopac Electrical Stimulator, which sends small electrical currents to the spinal cord through patches on the skin. The goal is to see if this stimulation is safe and can help prevent breathing muscles from getting weak while patients are on a ventilator. We are looking for 20 participants, including those having elective surgery and those with ARDS. The main thing we'll be watching for is any side effects from the stimulation over a period of 1 to 48 months.

Study design
This is an early-stage study with 20 participants, divided into two groups: 10 elective surgery patients and 10 ARDS patients.
What's involved
The study involves receiving spinal cord stimulation, with initial mapping to find the best electrode placement, followed by treatment stimulation.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for significant side effects for up to 48 months after the stimulation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05928052

Spinal Cord Stimulation to Shorten Ventilator Dependence in ARDS Patients

Recruiting
NAAges 18+InterventionalPrevention
University of California, Los Angeles
~20 participants
Updated 2025-03-10 on ClinicalTrials.gov
What's tested:Transcutaneous Biopac Electrical Stimulator

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recording of significant stimulation-induced adverse events (AE)
Measured over 1-48 months

Conditions

Respiratory Distress Syndrome

Explore related trials

Post-operativeRespiratory Distress Syndrome

NCT05928052

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California, Los Angeles

    Los Angeles, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Daniel Lu, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

Daniel Lu, MD, PhD
[email protected]
310-825-4321
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Recording of significant stimulation-induced adverse events (AE)1-48 months

    Although unlikely, we will record and monitor the number of stimulation-induced adverse events per case and per cohort. Our goal is to have an overall AE rate of less than 10% per cohort.